Eculizumab: ALXN completed enrollment of 115 patients in a placebo-controlled U.S. Phase II study of eculizumab. The product also is in Phase II testing to trea

Alexion Pharmaceuticals Inc. (ALXN), New Haven, Conn. Product: Eculizumab ( 5G1.1) Business: Musculoskeletal Therapeutic category: Antibody Target: Complement C5 Description: Humanized monoclonal ant...